(T 95) A post-hoc assessment of the impact of headache-free interictal period duration and every other day treatment with rimegepant on quality of life scores in a 12-week randomized placebo-controlled trial of migraine prevention

Geisel Professor of Neurology; Vice President, NEINH
The New England Institute for Neurology and Headache, Stamford, CT, USA
Pound Ridge, NY, United States

Pfizer Inc., Collegeville, PA, USA
Collegeville, Pennsylvania, United States

Pfizer Inc., Groton, CT, USA
Groton, Connecticut, United States

Pfizer Inc., Princeton, NJ, USA
Princeton, New Jersey, United States

Pfizer Inc., Collegeville, PA, USA, United States

Pfizer R&D UK Ltd., Tadworth, Surrey, UK, United Kingdom

Pfizer Ltd, Tadworth, Surrey, UK
Walton Oaks, England, United States

Director, Health Economics & Outcomes Research, Migraine
Pfizer R&D UK Ltd, Tadworth, Surrey, UK
Walton Oaks, England, United States